Article

End Points and Trial Design in Geriatric Oncology Research: A Joint European Organisation for Research and Treatment of Cancer-Alliance for Clinical Trials in Oncology-International Society of Geriatric Oncology Position Article

Harvey Jay Cohen, Duke University, Durham
Journal of Clinical Oncology (Impact Factor: 18.43). 09/2013; 31(29). DOI: 10.1200/JCO.2013.49.6125
Source: PubMed

ABSTRACT

Selecting the most appropriate end points for clinical trials is important to assess the value of new treatment strategies. Well-established end points for clinical research exist in oncology but may not be as relevant to the older cancer population because of competing risks of death and potentially increased impact of therapy on global functioning and quality of life. This article discusses specific clinical end points and their advantages and disadvantages for older individuals.Randomized or single-arm phase II trials can provide insight into the range of efficacy and toxicity in older populations but ideally need to be confirmed in phase III trials, which are unfortunately often hindered by the severe heterogeneity of the older cancer population, difficulties with selection bias depending on inclusion criteria, physician perception, and barriers in willingness to participate. All clinical trials in oncology should be without an upper age limit to allow entry of eligible older adults. In settings where so-called standard therapy is not feasible, specific trials for older patients with cancer might be required, integrating meaningful measures of outcome. Not all questions can be answered in randomized clinical trials, and large observational cohort studies or registries within the community setting should be established (preferably in parallel to randomized trials) so that treatment patterns across different settings can be compared with impact on outcome. Obligatory integration of a comparable form of geriatric assessment is recommended in future studies, and regulatory organizations such as the European Medicines Agency and US Food and Drug Administration should require adequate collection of data on efficacy and toxicity of new drugs in fit and frail elderly subpopulations.

  • Source
    • "Although older patients account for a majority of patients, they are often undertreated with standard chemotherapy regimens, largely due to a perception of poorer performance status, comorbidities, and anticipated intolerance to toxicity from platinum-based chemotherapy (Hardy et al, 2009;Davidoff et al, 2010;Langer, 2011). In addition, few studies have assessed treatment effects on quality of life (QoL) in elderly advanced NSCLC patients, and research on tolerability and toxicity profiles of chemotherapies in this population is similarly limited (Jang et al, 2009;Wildiers et al, 2013). Evidence, however, exists to show that platinum-based doublet chemotherapy is preferable to single-agent therapy for elderly, advanced NSCLC patients with good performance status who are likely to tolerate such therapy (Quoix et al, 2011;Qi et al, 2012). "
    [Show abstract] [Hide abstract]
    ABSTRACT: This analysis compared the quality-adjusted survival and clinical outcomes of albumin-bound paclitaxel+carboplatin (nab-PC) vs solvent-based paclitaxel+carboplatin (sb-PC) as first-line therapy in advanced non-small-cell lung cancer (NSCLC) in older patients. Using age-based subgroup data from a randomised Phase-3 clinical trial, nab-PC and sb-PC were compared with respect to overall response rate (ORR), overall survival (OS), progression-free survival (PFS), quality of life (QoL), safety/toxicity, and quality-adjusted time without symptoms or toxicity (Q-TWiST) with ages ⩾60 and ⩾70 years as cut points. Among patients aged ⩾60 years (N=546), nab-PC (N=265) significantly increased ORR and prolonged OS, despite a non-significant improvement in PFS, vs sb-PC (N=281). Nab-PC improved QoL and was associated with less neuropathy, arthralgia, and myalgia but resulted in more anaemia and thrombocytopenia. Nab-PC yielded significant Q-TWiST benefits (11.1 vs 9.8 months; 95% CI of gain: 0.2-2.6), with a relative Q-TWiST gain of 10.8% (ranging from 6.4% to 15.1% in threshold analysis). In the ⩾70 years age group, nab-PC showed similar, but non-significant, ORR, PFS, and Q-TWiST benefits and significantly improved OS and QoL. Nab-PC as first-line therapy in older patients with advanced NSCLC increased ORR, OS, and QoL and resulted in quality-adjusted survival gains compared with standard sb-PC.British Journal of Cancer advance online publication, 2 June 2015; doi:10.1038/bjc.2015.181 www.bjcancer.com.
    Full-text · Article · Jun 2015 · British Journal of Cancer
  • Source
    • "Thus, a large proportion of patients are denied the benefit of aggressive treatment. Moreover, many of the prospective clinical trials have excluded this group of patients from the trials, and thus, no worthwhile clinical studies were forthcoming from this age group, especially in developing countries [6] [7]. Therefore, there seems to be a need to integrate and optimize treatment planning for elderly cancer patients to achieve an improved tumor control, quality of life, and survival with better health care [5] [8]-[10]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: As a result of vast global improvement of health care and living conditions, the world population is aging. In developed countries, more than half of the cancers occur in patients aged 70 and older. In booming Asian nations, such as India, the aging trend is particularly striking, and therefore geria-tric oncology is rapidly coming at the foreground of oncology practice. As these patients have special needs and a different approach to treatment, there is a strong need for the emergence of ge-riatric oncology as a sub specialty in oncology. Scientific data show that a geriatric assessment identifies many problems in older people with cancer, adds prognostic information, and might improve the outcomes of these patients. There is a genuine unmet requirement to design and implement the following: development of individually tailored geriatric assessment tools for different oncology centers; cooperation of aging and cancer research in the understanding of cancer biology , aging and physiology; improved clinical study designs; development of geriatric oncology programs; and screening tools for geriatric patients made accessible to family physicians.
    Full-text · Article · Mar 2015 · International Journal of Medical Physics, Clinical Engineering and Radiation Oncology
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Cancer incidence increases with age. With an ageing population, the burden of cancer in older people is set to increase significantly in the coming decades. This is a heterogeneous group with wide variations in health and functional status separate from chronological age. Data suggest that historically this patient cohort have poorer outcomes and have been under-represented in clinical cancer trials. There is an emerging body of evidence to help guide treatment; however, ongoing research is needed to develop comprehensive evidence-based guidelines and identify treatment regimens, which are suitable for frailer patients. In this article, we review the current field of geriatric oncology. We highlight that age is not a contradiction to cancer treatment but geriatric assessment is needed to identify which treatment a patient may tolerate and benefit from.
    Full-text · Article · Jan 2014 · Forum of Clinical Oncology
Show more